Helicobacter pylori infection
Conditions
Interventions
Ilaprazole dual therapy group:High-dose ilaprazole dual therapy
Voronolasan in combination:High-dose vonoprazan dual group
Sponsors
Shenzhen Hospital of Southern Medical Unversity
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Age of 18-65 years old (inclusive of the cut-off value), male and female. 2. A positive 13C or 14C-urea breath test within 90 days and the need for Hp eradication therapy. 3. Treatment-naive patients without previous Hp eradication therapy. 4. Gastroscopic diagnosis report within 1 year. 5. No use of antibiotics and bismuth drugs within 30 days before treatment, and no use of PPI, potassium competitive acid blockers, H2 receptor antagonists and other acid inhibitor drugs within 14 days before treatment. 6. Sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with acute upper gastrointestinal bleeding, gastrointestinal malignant tumor, Zolet-Ellison syndrome, history of esophageal and gastric surgery, reflux esophagitis, gastric ulcer, Crohn's disease, ulcerative colitis. 2. Have serious heart, liver, lung, kidney, blood, endocrine system diseases, and the condition is not under control. 3. Pregnant or lactating women; 4. Ilaprazole or other benzimidazoles, penicillin allergy or idiosyncracies. 5. Participants who participated in other interventional drug clinical trials within 3 months before the trial. 6. Alcoholism or drug addiction. 7. The investigator decided that it was not appropriate to participate in the study for other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| H. pylori eradication rate; | — |
Countries
China
Contacts
Public ContactChenye
Southern Medical University Southern Hospital
Outcome results
None listed